Accelerated ART Initiation for PWHIV Who Are Out of Care
{ "Accelerated ART Initiation for People with HIV Who Are Out of Care", "This study is testing a new way to help people with HIV (PWHIV) who have stopped their treatment get back into care quickly. It's called the ACCELERATE model. This model involves the study team reaching out to you, offering a telehealth appointment with an HIV doctor within 24 business hours, and providing a simplified HIV medication called bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) along with a free 30-day starter supply. The main goal is to see if this approach helps people achieve viral suppression (meaning the amount of HIV in their blood is very low) within 24 weeks. The study also looks at how easy and helpful this model is for both patients and staff. You can join if you are 18 or older, speak English, and can understand and follow study instructions.", "design": "This is a single-arm study, meaning all 120 planned participants will receive the ACCELERATE model of care. It is designed to evaluate the effectiveness of this new approach.", "commitments": "You would have a telehealth appointment with an HIV care provider, receive a 30-day supply of medication, and be re-linked to medical care. Your viral suppression will be measured at 24 weeks, and your experience with the model will be assessed for up to 1 year.", "compensation": "Not stated in the trial record.", "follow_up": "The study will measure the effectiveness of the care model at 24 weeks and assess its acceptability and appropriateness for up to 1 year.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Accelerated ART Initiation for PWHIV Who Are Out of Care
At a glance
Conditions
Where it's being run
4 sites across 1 statesStudy leadership
- Dima Dandachi, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Missouri-Columbia
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- The effectiveness of the ACCELERATE model of care to achieve HIV viral suppression at Week 24.24 weeks
Proportion of participants who have plasma HIV RNA \<200 c/mL at Week 24 (observed analysis)
- To study the change over time in the acceptability of the ACCELERATE model of care in patient and staff participants.1 year
Quantitative Change in the mean scores of the Acceptability of Intervention Measure (AIM) scores at Weeks 24, and 48 by PLWH Change in the mean scores of the Acceptability of Intervention Measure (AIM)scores from baseline at Week 48 by Staff participants. Min score: 4 (worst) Max score: 20 (best)
- To study the change over time in appropriateness of the ACCELERATE model of care in patient and staff participants1 year
Quantitative Change in the mean scores of the Intervention Appropriateness Measure (IAM) scores at Weeks 24, and 48 by PLWH Change in the mean scores of the Intervention Appropriateness Measure (IAM) scores from baseline at Week 48 by Staff participants. Min score: 4 (worst) Max score: 20 (best)
- To study the change over time in feasibility of the ACCELERATE model of care in staff participants1 year
Quantitative Change in the mean scores of the Feasibility of Intervention Measure (FIM) scores from baseline at Weeks 24, and 48 by PLWH Change in the mean scores of the Feasibility of Intervention Measure (FIM) scores from baseline at Week 48 by Staff participants. Min score: 4 (worst) Max score: 20 (best)
- To study the change over time in sustainability of the ACCELERATE model of care in staff participants1 year
Quantitative Mean overall score of Clinical Sustainability Assessment Tool (CSAT) and change from baseline at Week 48 by Staff participants. Min score: 0 (worst) Max score: 147 (best)
- Qualitative data1 year
One-on-one Semi-structured interviews with PLWH and Staff Participants at end of study.